Replies to post #162619 on Biotech Values

[mcbio]

Array BioPharma Announces Positive Interim Results From Combination Trial Of ARRY-520 With Kyprolis At The 2013 European Hematology Association Congress

Here's a link to the poster: http://arraybiopharma.com/_documents/Publication/PubAttachment574.pdf . Per the poster, the combo has not reached MTD and there have been 4 patients so far in the highest-dose cohort of 1.5 mg/day. Also, of the 17 total patients in the trial so far, 8 are still receiving therapy. Finally, a Phase 1b dose expansion is planned at the MTD or maximum planned dose (MPD) of the first part of the trial. It also sounds like there will be a dose escalation of carfilzomib in Part B of the trial once the MTD or MPD of 520 is established in Part A. So, it would seem there's room for further efficacy of the combo, provided the safety of the combo cooperates.